A Three-Dimensional Ply Failure Model for Composite Structures

A fully 3D failure model to predict damage in composite structures subjected to multiaxial loading is presented in this paper. The formulation incorporates shear nonlinearities effects, irreversible strains, damage and strain rate effects by using a viscoplastic damageable constitutive law. The proposed formulation enables the prediction of failure initiation and failure propagation by combining stress-based, damage mechanics and fracture mechanics approaches within an unified energy based context. An objectivity algorithm has been embedded into the formulation to avoid problems associated with strain localization and mesh dependence. The proposed model has been implemented into ABAQUS/Explicit FE code within brick elements as a userdefined material model. Numerical predictions for standard uniaxial tests at element and coupon levels are presented and discussed

k-Component q-deformed charge coherent states and their nonclassical properties

k-Component q-deformed charge coherent states are constructed, their (over)completeness proved and their generation explored. The q-deformed charge coherent states and the even (odd) q-deformed charge coherent states are the two special cases of them as k becomes 1 and 2, respectively. A D-algebra realization of the SU$_q$(1,1) generators is given in terms of them. Their nonclassical properties are studied and it is shown that for $k\geq3$, they exhibit two-mode q-antibunching, but neither SU$_q$(1,1) squeezing, nor one- or two-mode q-squeezing.Comment: LaTeX, 29 pages, 2 Postscript figures, minor change

Tailored postoperative treatment of prostate cancer: final results of a phase I/II trial.

BACKGROUD: The European Organization for Research and Treatment of Cancer (EORTC) trial 22,911 reported 74% 5-year biochemical disease-free survival (bDFS) in patients with prostate carcinoma treated with radical prostatectomy (RP) followed by postoperative radiotherapy (RT). This study aimed to improve these outcomes by using a combined-intensified-modulated-adjuvant treatment, including RT and hormone therapy (HT) after RP. MATERIALS AND METHODS: This phase I/II trial treatment was designed to improve 5-year bDFS from ~\u200975 to 90%. Patients were consecutively enrolled using the following inclusion criteria: age\u2009<\u200980 years, histological diagnosis of prostate adenocarcinoma without known metastases, stage pT2-4N0-1, and Eastern Cooperative Oncology Group performance status of 0-2. All patients had at least one of these pathologic features: capsular perforation, positive surgical margins, seminal vesicle invasion, and pelvic lymph nodes involvement. A minimum dose of 64.8\u2009Gy to the tumor bed was delivered in all patients. Depending on tumor characteristics at diagnosis, patients received a higher dose (70.2\u2009Gy; 85.4%) and/or prophylactic pelvic lymph nodes irradiation (57.7%) and/or HT (69.1%). Biochemical relapse was defined as two consecutive rising prostate-specific antigen (PSA) values\u2009>\u20090.2\u2009ng/ml. RESULTS: A total of 123 patients were enrolled in the study and completed the scheduled treatment. Median preoperative and postoperative PSA were: 8.8 and 0.06\u2009ng/mL, respectively. The percentages of patients with pathologically involved nodes and positive resection margins were: 14.6% and 58.5%, respectively. With a median follow-up of 67 months (range: 37-120 months), the actuarial 5-year bDFS, local control, metastasis-free survival, and overall survival (OS) were: 92.9%, 98.7%, 96.1%, and 95.1%, respectively. CONCLUSION: A higher 5-year bDFS (92.9%) was recorded compared to studies based on standard adjuvant RT, even though patients with nodal disease and detectable postoperative PSA were enrolled. Clinical end points, as long-term disease-free survival and OS, will require further assessments